-
公开(公告)号:US07923563B2
公开(公告)日:2011-04-12
申请号:US11663550
申请日:2005-10-25
申请人: Ikuo Kushida , Eriko Doi , Koichi Ito
发明人: Ikuo Kushida , Eriko Doi , Koichi Ito
IPC分类号: C07D401/06
CPC分类号: C07D401/10
摘要: An amorphous object of (3E)-1-[l(s)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the formula (1) and has Aβ-production inhibitory activity. The amorphous object has such satisfactory properties that it has excellent solubility, is stable, does not readily become a crystalline form, and has low hygroscopicity. It is hence suitable for use in pharmaceutical preparations.
摘要翻译: (3E)-1- [1(S)-1-(4-氟苯基)乙基] -3- [3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基] (1)表示并具有生产抑制活性。 无定形物具有这样令人满意的性质,其具有优异的溶解性,稳定性,不容易变成结晶形式,并且具有低吸湿性。 因此适用于药物制剂。
-
公开(公告)号:US20090048448A1
公开(公告)日:2009-02-19
申请号:US12093929
申请日:2006-11-17
申请人: Ikuo Kushida , Eriko Doi , Koichi Ito , Taiju Nakamura
发明人: Ikuo Kushida , Eriko Doi , Koichi Ito , Taiju Nakamura
IPC分类号: C07D401/10
CPC分类号: C07D401/10
摘要: The invention provides crystals of dihydrochloride monohydrate of the compound of the following formula having an Aβ production inhibiting effect which crystals are characterized by exhibiting a diffraction peak at an angle of diffraction (2θ±0.2°) of 10.9° in powder X-ray diffractometry. Further, the invention also provides the compound in the form of various salts, crystal forms and amorphous forms which are suitable for the development of drugs.
摘要翻译: 本发明提供下式化合物的二盐酸盐一水合物晶体,其具有抑制Aβ生成的作用,其结晶的特征在于在粉末X射线衍射中以衍射角(2θ±0.2°)为10.9°的衍射峰。 此外,本发明还提供了适合于开发药物的各种盐,晶型和无定形形式的化合物。
-
公开(公告)号:US20090203916A1
公开(公告)日:2009-08-13
申请号:US11663550
申请日:2005-10-25
申请人: Ikuo Kushida , Eriko Doi , Koichi Ito
发明人: Ikuo Kushida , Eriko Doi , Koichi Ito
IPC分类号: C07D401/10
CPC分类号: C07D401/10
摘要: An amorphous object of (3E)-1-[l(s)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the formula (1) and has Aβ-production inhibitory activity. The amorphous object has such satisfactory properties that it has excellent solubility, is stable, does not readily become a crystalline form, and has low hygroscopicity. It is hence suitable for use in pharmaceutical preparations.
摘要翻译: (3E)-1- [1(S)-1-(4-氟苯基)乙基] -3- [3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基] (1)表示,具有Abeta生产抑制活性。 无定形物具有这样令人满意的性质,其具有优异的溶解性,稳定性,不容易变成结晶形式,并且具有低吸湿性。 因此适用于药物制剂。
-
公开(公告)号:US07897632B2
公开(公告)日:2011-03-01
申请号:US12721952
申请日:2010-03-11
申请人: Teiji Kimura , Noritaka Kitazawa , Toshihiko Kaneko , Nobuaki Sato , Koki Kawano , Koichi Ito , Eriko Doi , Mamoru Takaishi , Takeo Sasaki , Takehiko Miyagawa , Hiroaki Hagiwara , Takashi Doko
发明人: Teiji Kimura , Noritaka Kitazawa , Toshihiko Kaneko , Nobuaki Sato , Koki Kawano , Koichi Ito , Eriko Doi , Mamoru Takaishi , Takeo Sasaki , Takehiko Miyagawa , Hiroaki Hagiwara , Takashi Doko
IPC分类号: C07D471/04 , C07D498/04 , A61K31/5383 , A61K31/5025
CPC分类号: C07D403/10 , C07D471/04 , C07D498/04
摘要: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
摘要翻译: 本发明提供由式(I)表示的化合物或其药理学上可接受的盐,其中Ar 1表示可被C 1-6烷基取代的咪唑基等,Ar 2表示可以 被C 1-6烷氧基等取代,X 1表示双键等,Het表示可被C 1-6烷基取代的咪唑基等,其作为式 由A&Bgr引起的疾病的治疗或预防剂。
-
公开(公告)号:US07713993B2
公开(公告)日:2010-05-11
申请号:US11715440
申请日:2007-03-08
申请人: Teiji Kimura , Noritaka Kitazawa , Toshihiko Kaneko , Nobuaki Sato , Koki Kawano , Koichi Ito , Eriko Doi , Mamoru Takaishi , Takeo Sasaki , Takehiko Miyagawa , Hiroaki Hagiwara , Takashi Doko
发明人: Teiji Kimura , Noritaka Kitazawa , Toshihiko Kaneko , Nobuaki Sato , Koki Kawano , Koichi Ito , Eriko Doi , Mamoru Takaishi , Takeo Sasaki , Takehiko Miyagawa , Hiroaki Hagiwara , Takashi Doko
IPC分类号: C07D471/04 , C07D498/04 , A61K31/5383 , A61K31/5025
CPC分类号: C07D403/10 , C07D471/04 , C07D498/04
摘要: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
摘要翻译: 本发明提供由式(I)表示的化合物或其药理学上可接受的盐,其中Ar 1表示可被C 1-6烷基取代的咪唑基等,Ar 2表示可以 被C 1-6烷氧基等取代,X 1表示双键等,Het表示可被C 1-6烷基取代的咪唑基等,其作为式 由A&Bgr引起的疾病的治疗或预防剂。
-
公开(公告)号:US20100113773A1
公开(公告)日:2010-05-06
申请号:US12522281
申请日:2008-02-27
申请人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Mamoru Takaishi , Koichi Ito , Toshihiko Kaneko , Takeo Sasaki , Nobuaki Sato , Takehiko Miyagawa , Hiroaki Hagiwara
发明人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Mamoru Takaishi , Koichi Ito , Toshihiko Kaneko , Takeo Sasaki , Nobuaki Sato , Takehiko Miyagawa , Hiroaki Hagiwara
IPC分类号: C07D498/04
CPC分类号: C07D498/04
摘要: The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
摘要翻译: 本发明涉及由式(I)表示的化合物:其中R1表示C1-3烷基,R2表示氢原子或C1-3烷基,Ar表示可被基团取代的苯基等 1〜3个取代基,X表示氧原子等,n和m相同或不同,为0〜2的整数,或药理学上可接受的盐及其作为药物的用途。
-
公开(公告)号:US07687640B2
公开(公告)日:2010-03-30
申请号:US12497251
申请日:2009-07-02
申请人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
发明人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
IPC分类号: C07D233/56 , A01N43/50
CPC分类号: C07D401/10 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/04
摘要: The present invention relates to a process for preparing a compound of formula (6a): wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Ar2 represents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and R11 represents a group selected from certain substituents.
摘要翻译: 本发明涉及式(6a)化合物的制备方法:其中Ar 1表示可被1〜3个取代基取代的咪唑基, Ar 2表示吡啶基,嘧啶基或可被1〜3个取代基取代的苯基; R 11表示选自某些取代基的基团。
-
公开(公告)号:US20110086860A1
公开(公告)日:2011-04-14
申请号:US12974447
申请日:2010-12-21
申请人: Teiji KIMURA , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
发明人: Teiji KIMURA , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
IPC分类号: A61K31/497 , C07D233/54 , C07D403/10 , C07D401/04 , C07D241/00 , A61K31/4164 , A61K31/4178 , A61K31/454 , A61P25/28
CPC分类号: C07D401/10 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/04
摘要: A compound represented by Formula (I) is provided: wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc., which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group which may be substituted, or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.
摘要翻译: 提供由式(I)表示的化合物:其中Ar 1表示可被1至3个取代基取代的咪唑基; Ar2表示可被1〜3个取代基取代的苯基; X1表示(1)-C≡C-或(2)双键等,其可以被取代; R1和R2表示例如可被取代的C1-6烷基或其药理学上可接受的盐及其作为药剂的用途。
-
公开(公告)号:US07880009B2
公开(公告)日:2011-02-01
申请号:US11596723
申请日:2005-05-25
申请人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
发明人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Kogyoku Shin , Takehiko Miyagawa , Toshihiko Kaneko , Koichi Ito , Mamoru Takaishi , Takeo Sasaki , Hiroaki Hagiwara
IPC分类号: C07D405/00 , A61K31/445
CPC分类号: C07D401/10 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/04
摘要: The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.
摘要翻译: 本发明涉及由式(I)表示的化合物:其中Ar 1表示可被1〜3个取代基取代的咪唑基; Ar 2表示吡啶基,嘧啶基或可被 1〜3个取代基; X1表示(1)-C≡C-或(2)可被取代的双键等; R 1和R 2表示例如C 1-6烷基或C 3-8环烷基, 可以被取代)或其药理学上可接受的盐及其作为药剂的用途。
-
公开(公告)号:US07618960B2
公开(公告)日:2009-11-17
申请号:US11594130
申请日:2006-11-08
申请人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Mamoru Takaishi , Koichi Ito , Toshihiko Kaneko , Takeo Sasaki , Nobuaki Sato , Takehiko Miyagawa , Hiroaki Hagiwara
发明人: Teiji Kimura , Koki Kawano , Eriko Doi , Noritaka Kitazawa , Mamoru Takaishi , Koichi Ito , Toshihiko Kaneko , Takeo Sasaki , Nobuaki Sato , Takehiko Miyagawa , Hiroaki Hagiwara
IPC分类号: C07D498/04 , A61K31/5375
CPC分类号: C07D413/10 , C07D401/10 , C07D401/14 , C07D405/14 , C07D413/14
摘要: The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.
摘要翻译: 本发明涉及由式(I)表示的化合物或其药理学上可接受的盐,其中R 1,R 2,R 3和R 4相同或不同,各自表示氢原子或C 1-6烷基; X 1表示可以被取代的C 1-6亚烷基; Xa表示甲氧基或氟原子; Xb表示氧原子或亚甲基,条件是当Xa为甲氧基时Xb仅为氧原子; Ar 1表示可以具有卤素原子等取代基的芳基,吡啶基,芳氧基或吡啶氧基; 并使用化合物或盐作为药剂。
-
-
-
-
-
-
-
-
-